P
Paul Haluska
Researcher at Mayo Clinic
Publications - 132
Citations - 6300
Paul Haluska is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 38, co-authored 132 publications receiving 5708 citations. Previous affiliations of Paul Haluska include Merck & Co. & Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells
Marta Santisteban,Jennifer M. Reiman,Michael K. Asiedu,Marshall Behrens,Aziza Nassar,Kimberly R. Kalli,Paul Haluska,James N. Ingle,Lynn C. Hartmann,Masoud H. Manjili,Derek C. Radisky,Soldano Ferrone,Keith L. Knutson +12 more
TL;DR: It is found that EMT was induced by CD8 T cells and the resulting tumors had characteristics of BCSCs, including potent tumorigenicity, ability to reestablish an epithelial tumor, and enhanced resistance to drugs and radiation.
Journal ArticleDOI
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
David Olmos,Sophie Postel-Vinay,L Rhoda Molife,Scott H. Okuno,Scott M. Schuetze,M. Luisa Paccagnella,Gretchen N. Batzel,Donghua Yin,Kathryn Pritchard-Jones,Ian Judson,Francis P. Worden,Antonio Gualberto,Michelle Scurr,Johann S. de Bono,Paul Haluska +14 more
TL;DR: Figitumumab is well tolerated and has antitumour activity in Ewing's sarcoma, warranting further investigation in this disease.
Journal ArticleDOI
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis,Lynn C. Hartmann,William A. Cliby,Harry J. Long,Prema P. Peethambaram,Brigitte A. Barrette,Judith S. Kaur,Paul Haluska,Ileana Aderca,Paula J. Zollman,Jeff A. Sloan,Gary L. Keeney,Pamela J. Atherton,Karl C. Podratz,Sean C. Dowdy,C. Robert Stanhope,Timothy O. Wilson,Mark J. Federspiel,Kah-Whye Peng,Stephen J. Russell +19 more
TL;DR: The findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients.
Journal ArticleDOI
Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer
Daniel D. Karp,Luis Paz-Ares,Silvia Novello,Paul Haluska,Linda L. Garland,Felipe Cardenal,L. Johnetta Blakely,Peter D. Eisenberg,Corey J. Langer,George R. Blumenschein,Faye M. Johnson,Stephanie J. Green,Antonio Gualberto +12 more
TL;DR: The data suggest that PCI(20) is safe and effective in patients with NSCLC, and responsive to treatment in two patients with squamous cell carcinoma histology.
Journal ArticleDOI
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Paul Haluska,Heather Shaw,Gretchen N. Batzel,Donghua Yin,Julian R. Molina,L Rhoda Molife,Timothy A. Yap,Roberts Maria Luisa,Amarnath Sharma,Antonio Gualberto,Alex A. Adjei,Johann S. de Bono +11 more
TL;DR: CP-751,871 has a favorable safety profile and was well tolerated when given in continuous cycles, and at the maximal feasible dose of 20 mg/kg, there was a moderate accumulation in plasma exposure, and most of the treated patients experienced stability of disease.